|

Sonrotoclax Clinical Trials

9 actively recruiting trials across 6 locations

Also known as: B-cell Lymphoma-2 Inhibitor BGB-11417, BGB 11417, BGB-11417, BGB11417, Bcl-2 Inhibitor BGB-11417

Pipeline

Phase 1: 1Phase 2: 3Phase 3: 3Phase 1/2: 2

Top Sponsors

  • BeOne Medicines5
  • Massachusetts General Hospital1
  • Fred Hutchinson Cancer Center1
  • City of Hope Medical Center1
  • Christine Ryan1

Indications

  • Cancer9
  • Chronic Lymphocytic Leukemia4
  • Mantle Cell Lymphoma3
  • Refractory Mantle Cell Lymphoma2
  • Small Lymphocytic Lymphoma2

Birmingham, Alabama2 trials

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

University of Alabama At Birmingham Hospital

Phase 1/2
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

University of Alabama At Birmingham Hospital

Phase 3

Phoenix, Arizona2 trials

A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

Mayo Clinic Phoenix

Phase 1/2
BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma

Mayo Clinic Arizona

Phase 2

Other1 trial

A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Phase 3

Duarte, California1 trial

Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

City of Hope Medical Center

Phase 1

Laguna Hills, California1 trial

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

Uci Health Laguna Hills

Phase 3

Boston, Massachusetts1 trial

Zanubrutinib, Obinutuzumab, and Sonrotoclax in Previously Untreated Patients With CLL or SLL

Massachusetts General Hospital

Phase 2

Seattle, Washington1 trial

Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma

Fred Hutch/University of Washington Cancer Consortium

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.